ASCO Annual Meeting
Geriatric Assessment Rates Improve With Nurse Navigator Intervention
July 05, 2022
Article
Nurse navigators may play a key role in mitigating toxicities from chemotherapy and perform geriatric assessments for patients treated at hematology/oncology clinics.
Burbage Provides Nursing Perspective on 2022 ASCO Meeting
July 01, 2022
Article
Darcy Burbage, DNP, RN, AOCN, CBCN, discusses the top takeaways from the 2022 ASCO Annual Meeting for oncology nurses.
Expanded Safety Analysis from CheckMate 648 Shows Tolerability with Frontline Nivolumab Combinations in ESCC
June 29, 2022
Article
Data from the CheckMate 648 trial informed the FDA’s recent approval of 2 nivolumab combinations for esophageal squamous cell carcinoma. A 1-year follow-up analysis highlighted key safety and time-to-event data surrounding immune-related toxicities.
Oncology Nursing News’ Top ASCO Picks
June 28, 2022
Article
We rounded up 5 stories from the 2022 ASCO Annual Meeting that are of most value to oncology nurses.
Oral Minoxidil Demonstrates Efficacy in Treating Later Stage Alopecia in Cancer Survivors
June 27, 2022
Article
Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.
Adagrasib Demonstrates CNS Activity in KRAS G12C+ NSCLC
June 21, 2022
Article
The intracranial objective response rate was 32% among patients with KRAS G12C–mutant, non–small cell lung cancer who received adagrasib.
Roxadustat Increases Hemoglobin Counts in Patients With Chemotherapy-Induced Anemia
June 21, 2022
Article
Phase 2 findings found that patients with chemotherapy-induced anemia experienced increases in hemoglobin following treatment with roxadustat.
DRd Outperforms Rd in Newly Diagnosed Multiple Myeloma
June 19, 2022
Article
Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma.
Frontline Panitumumab/mFOLFOX Elicits Longest Overall Survival To-Date in RAS Wild-Type Metastatic CRC
June 18, 2022
Article
Phase 3 findings showed that panitumumab plus mFOLFOX significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer.
Patritumab Deruxtecan Produces Early Responses in Advanced NSCLC Regardless of Variant Genomic Alterations
June 17, 2022
Article
Regardless of other identified driver genomic alterations, patients with heavily pretreated, advanced, non–small cell lung cancer achieved encouraging responses with patritumab deruxtecan.